Immunovant (IMVT) Earnings Date, Estimates & Call Transcripts $17.89 -0.30 (-1.65%) Closing price 04:00 PM EasternExtended Trading$18.18 +0.29 (+1.62%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunovant Latest Earnings SummaryUpcoming Q4 Earnings DateJun. 4EstimatedActual EPS (Feb. 10) -$0.76 Missed By -$0.08 Consensus EPS (Feb. 10) -$0.68 Immunovant issued Q3 2025 earnings on February 10, 2025, reporting an EPS of -$0.76, which missed the consensus estimate of -$0.68 by $0.08. With a trailing EPS of -$2.62, Immunovant's earnings are expected to decrease next year, from ($2.69) to ($3.08) per share. SEC 10-Q/10-K FilingIMVT Upcoming EarningsImmunovant's next earnings date is estimated for Wednesday, June 4, 2025, based off prior year's reporting schedules. Get Immunovant Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIMVT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IMVT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Immunovant Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.57-$0.41-$0.50Q2 20254-$0.62-$0.54-$0.59Q3 20254-$0.64-$0.54-$0.59Q4 20254-$0.75-$0.56-$0.65FY 202515-$2.58-$2.05-$2.32Q1 20262-$0.82-$0.62-$0.72Q2 20262-$0.87-$0.64-$0.76Q3 20262-$0.86-$0.64-$0.75Q4 20262-$0.82-$0.67-$0.75FY 20268-$3.37-$2.57-$2.97Q1 20271-$0.87-$0.87-$0.87Q2 20271-$0.89-$0.89-$0.89Q3 20271-$0.91-$0.91-$0.91 Remove Ads Immunovant Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 6/4/2025(Estimated)-------2/10/2025Q3 2025-$0.68-$0.76 -$0.08-$0.76--11/7/2024Q2 2025-$0.59-$0.74 -$0.15-$0.74--8/6/2024Q1 2025-$0.53-$0.60 -$0.07-$0.60--5/29/2024Q4 2024-$0.44-$0.52 -$0.08-$0.52--2/12/2024Q4 2023-$0.43-$0.36+$0.07-$0.36--11/9/2023Q2 2024-$0.45-$0.45--$0.45--8/10/2023Q1 2024-$0.44-$0.47 -$0.03-$0.37--5/22/2023Q1 2023-$0.41-$0.46 -$0.05-$0.46-- Immunovant Earnings - Frequently Asked Questions When is Immunovant's earnings date? Immunovant has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 4th, 2025 based off last year's report dates. Learn more on IMVT's earnings history. Did Immunovant beat their earnings estimates last quarter? In the previous quarter, Immunovant (NASDAQ:IMVT) missed the analysts' consensus estimate of ($0.68) by $0.08 with a reported earnings per share (EPS) of ($0.76). Learn more on analysts' earnings estimate vs. IMVT's actual earnings. How can I view Immunovant's earnings report? Immunovant's earnings report can be found in their filing with the SEC. View SEC filing How much profit does Immunovant generate each year? Immunovant (NASDAQ:IMVT) has a recorded net income of -$259.34 million. IMVT has generated -$2.62 earnings per share over the last four quarters. What is Immunovant's EPS forecast for next year? Immunovant's earnings are expected to decrease from ($2.69) per share to ($3.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Moderna Earnings Genmab A/S Earnings Dr. Reddy's Laboratories Earnings Viatris Earnings Ascendis Pharma A/S Earnings Vaxcyte Earnings Qiagen Earnings Roivant Sciences Earnings Sarepta Therapeutics Earnings Revolution Medicines Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of Earnings Remove Ads This page (NASDAQ:IMVT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersElon Musk to roll out new AI project - make this move to profitA lot of folks don't realize this... But Elon Musk is set to become the world's first trillionaire... Th...InvestorPlace | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
